Literature DB >> 2276394

The relationship between debrisoquine oxidation phenotype and the pharmacokinetics of chlorpropamide.

J Kallio1, R Huupponen, K Pyykkö.   

Abstract

The pharmacokinetics and urinary metabolite pattern of a single oral dose of chlorpropamide 250 mg have been studied in 6 extensive and 5 poor metabolizers of debrisoquine. Ammonium chloride was given orally to acidify the urine in order to make elimination of the parent drug dependent on metabolism alone. The concentration profile in serum and the pharmacokinetic parameters of the parent drug were similar in both groups. However, the ratio in urine of unchanged chlorpropamide to its hydroxylated metabolites was higher in poor than in extensive metabolizers.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2276394     DOI: 10.1007/bf02657068

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  14 in total

1.  Pharmacokinetics and biotransformation of chlorpropamide in man.

Authors:  J A Taylor
Journal:  Clin Pharmacol Ther       Date:  1972 Sep-Oct       Impact factor: 6.875

2.  A study of the metabolic fate of chlorpropamide in man.

Authors:  P M Brotherton; P Grieveson; C McMartin
Journal:  Clin Pharmacol Ther       Date:  1969 Jul-Aug       Impact factor: 6.875

3.  Determination of serum tolbutamide and chlorpropamide by high-performance liquid chromatography.

Authors:  R E Hill; J Crechiolo
Journal:  J Chromatogr       Date:  1978-01-01

4.  Tolbutamide hydroxylation by human liver microsomes. Kinetic characterisation and relationship to other cytochrome P-450 dependent xenobiotic oxidations.

Authors:  J O Miners; K J Smith; R A Robson; M E McManus; M E Veronese; D J Birkett
Journal:  Biochem Pharmacol       Date:  1988-03-15       Impact factor: 5.858

5.  Measurement of antidiabetic sulfonylureas in serum by gas chromatography with electron-capture detection.

Authors:  W E Braselton; E D Bransome; T A Huff
Journal:  Diabetes       Date:  1977-01       Impact factor: 9.461

6.  Chlorpropamide bioavailability and pharmacokinetics.

Authors:  R Huupponen; R Lammintausta
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1981-07

Review 7.  Genetic variation in the human hepatic cytochrome P-450 system.

Authors:  W Kalow
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

8.  Chlorpropamide and glibenclamide serum concentrations in hospitalized patients.

Authors:  R Huupponen; J Viikari; H Saarimaa
Journal:  Ann Clin Res       Date:  1982-06

9.  Wide variation in serum chlorpropamide concentration in outpatients.

Authors:  U Bergman; I Christenson; B Jansson
Journal:  Eur J Clin Pharmacol       Date:  1980-08       Impact factor: 2.953

10.  Characterization of the common genetic defect in humans deficient in debrisoquine metabolism.

Authors:  F J Gonzalez; R C Skoda; S Kimura; M Umeno; U M Zanger; D W Nebert; H V Gelboin; J P Hardwick; U A Meyer
Journal:  Nature       Date:  1988-02-04       Impact factor: 49.962

View more
  1 in total

1.  Chlorpropamide 2-hydroxylation is catalysed by CYP2C9 and CYP2C19 in vitro: chlorpropamide disposition is influenced by CYP2C9, but not by CYP2C19 genetic polymorphism.

Authors:  Ji-Hong Shon; Young-Ran Yoon; Min-Jung Kim; Kyoung-Ah Kim; Young-Chae Lim; Kwang-Hyeon Liu; Dong-Hoon Shin; Chung Han Lee; In-June Cha; Jae-Gook Shin
Journal:  Br J Clin Pharmacol       Date:  2005-05       Impact factor: 4.335

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.